Skip to main content
Erschienen in: World Journal of Urology 11/2016

12.04.2016 | Original Article

Prostate cancer in men aged less than 50 years at diagnosis

verfasst von: N. J. Kinnear, G. Kichenadasse, S. Plagakis, M. E. O’Callaghan, T. Kopsaftis, S. Walsh, D. Foreman

Erschienen in: World Journal of Urology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Prostate cancer (CaP) in younger men (age ≤50 years) appears to present differently compared with older men. This study describes CaP characteristics and outcomes in Australian young men.

Methods

The South Australian Prostate Cancer Clinical Outcomes Collaborative database was used to identify men diagnosed with CaP 1998–2012. Men were stratified by age at diagnosis into groups ≤50, 50–70 and ≥70 years. Primary outcomes of cumulative biochemical recurrence (BCR) and cumulative prostate cancer-specific mortality (PCSM) were assessed at 5 and 10 years.

Results

In total, 7018 men were included. At time of diagnosis, 182 (2.6 %) were aged ≤50 years. Median follow-up exceeded 4 years. Younger men had a greater proportion of T stage <2 disease, lower median PSA and higher rates of Gleason score <7 (all p < 0.001). They were more likely to experience active surveillance (AS) (4.9, 3.1, 1.5 %) or radical prostatectomy (RP) (70, 55, 8 %) and less likely radiotherapy (13, 24, 29 %) as their principal modality (all p < 0.001). Although only 4.9 % underwent AS, 48 % of men ≤50 years were eligible for AS. Men ≤50 years had both the lowest unadjusted cumulative BCR and PCSM at 10 years. After multivariate analysis, BCR was not significantly different. Sample size limited multivariate analysis of PCSM.

Conclusions

In our cohort, men ≤50 years with CaP had less aggressive clinical characteristics, but were more likely to undergo RP. They appear to experience lower unadjusted PCSM, but similar rates of adjusted BCR. Further studies are needed to assess whether AS is appropriately utilised in these men.
Literatur
2.
Zurück zum Zitat Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS (1999) Cancer surveillance series: interpreting trends in prostate cancer–part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91(12):1017–1024CrossRefPubMed Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS (1999) Cancer surveillance series: interpreting trends in prostate cancer–part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91(12):1017–1024CrossRefPubMed
3.
Zurück zum Zitat Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK (1997) Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 158(4):1427–1430CrossRefPubMed Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK (1997) Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 158(4):1427–1430CrossRefPubMed
4.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2012. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Accessed 07 Aug 2015 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2012. National Cancer Institute. Bethesda, MD. http://​seer.​cancer.​gov/​csr/​1975_​2012/​, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Accessed 07 Aug 2015
6.
Zurück zum Zitat McCaul KA, Luke CG, Roder DM (1995) Trends in prostate cancer incidence and mortality rates in South Australia, 1977–1993. Med J Aust 162(10):520–522PubMed McCaul KA, Luke CG, Roder DM (1995) Trends in prostate cancer incidence and mortality rates in South Australia, 1977–1993. Med J Aust 162(10):520–522PubMed
8.
Zurück zum Zitat Ranasinghe WK, Kim SP, Lawrentschuk N, Sengupta S, Hounsome L, Barber J, Jones R, Davis P, Bolton D, Persad R (2014) Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia. BJU Int 113(1):77–83. doi:10.1111/bju CrossRefPubMed Ranasinghe WK, Kim SP, Lawrentschuk N, Sengupta S, Hounsome L, Barber J, Jones R, Davis P, Bolton D, Persad R (2014) Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia. BJU Int 113(1):77–83. doi:10.​1111/​bju CrossRefPubMed
10.
Zurück zum Zitat Tjaden HB, Culp DA, Flocks RH (1965) Clinical adenocarcinoma of the prostate in patients under 50 years of age. J Urol 93:618–621PubMed Tjaden HB, Culp DA, Flocks RH (1965) Clinical adenocarcinoma of the prostate in patients under 50 years of age. J Urol 93:618–621PubMed
11.
Zurück zum Zitat Grönberg H, Damber L, Jonson H, Damber JE (1997) Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. Urology 49(3):374–378CrossRefPubMed Grönberg H, Damber L, Jonson H, Damber JE (1997) Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. Urology 49(3):374–378CrossRefPubMed
13.
Zurück zum Zitat Smith CV, Bauer JJ, Connelly RR, Seay T, Kane C, Foley J, Thrasher JB, Kusuda L, Moul JW (2000) Prostate cancer in men age 50 years or younger: a review of the department of defense center for prostate disease research multicenter prostate cancer database. J Urol 164(6):1964–1967CrossRefPubMed Smith CV, Bauer JJ, Connelly RR, Seay T, Kane C, Foley J, Thrasher JB, Kusuda L, Moul JW (2000) Prostate cancer in men age 50 years or younger: a review of the department of defense center for prostate disease research multicenter prostate cancer database. J Urol 164(6):1964–1967CrossRefPubMed
14.
Zurück zum Zitat Becker A, Tennstedt P, Hansen J, Trinh QD, Kluth L, Atassi N, Schlomm T, Salomon G, Haese A, Budaeus L, Michl U, Heinzer H, Huland H, Graefen M, Steuber T (2014) Functional and oncological outcomes of patients aged < 50 years treated with radical prostatectomy for localised prostate cancer in a European population. BJU Int 114(1):38–45. doi:10.1111/bju.12407 CrossRefPubMed Becker A, Tennstedt P, Hansen J, Trinh QD, Kluth L, Atassi N, Schlomm T, Salomon G, Haese A, Budaeus L, Michl U, Heinzer H, Huland H, Graefen M, Steuber T (2014) Functional and oncological outcomes of patients aged < 50 years treated with radical prostatectomy for localised prostate cancer in a European population. BJU Int 114(1):38–45. doi:10.​1111/​bju.​12407 CrossRefPubMed
17.
Zurück zum Zitat Heyns CF, Fisher M, Lecuona A, Van der Merwe A (2011) Should baseline PSA testing be performed in men aged 40 to detect those aged 50 or less who are at risk of aggressive prostate cancer? S Afr Med J 101(9):642–644PubMed Heyns CF, Fisher M, Lecuona A, Van der Merwe A (2011) Should baseline PSA testing be performed in men aged 40 to detect those aged 50 or less who are at risk of aggressive prostate cancer? S Afr Med J 101(9):642–644PubMed
18.
Zurück zum Zitat Spangler E, Zeigler-Johnson CM, Malkowicz SB, Wein AJ, Rebbeck TR (2005) Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors. Int J Cancer 113(3):471–474CrossRefPubMed Spangler E, Zeigler-Johnson CM, Malkowicz SB, Wein AJ, Rebbeck TR (2005) Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors. Int J Cancer 113(3):471–474CrossRefPubMed
19.
Zurück zum Zitat Khan MA, Han M, Partin AW, Epstein JI, Walsh PC (2003) Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 62(1):86–91CrossRefPubMed Khan MA, Han M, Partin AW, Epstein JI, Walsh PC (2003) Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 62(1):86–91CrossRefPubMed
20.
Zurück zum Zitat Freedland SJ, Presti JC Jr, Kane CJ, Aronson WJ, Terris MK, Dorey F, Amling CL, SEARCH Database Study Group (2004) Do younger men have better biochemical outcomes after radical prostatectomy? Urology 63(3):518–522CrossRefPubMed Freedland SJ, Presti JC Jr, Kane CJ, Aronson WJ, Terris MK, Dorey F, Amling CL, SEARCH Database Study Group (2004) Do younger men have better biochemical outcomes after radical prostatectomy? Urology 63(3):518–522CrossRefPubMed
21.
Zurück zum Zitat Twiss C, Slova D, Lepor H (2005) Outcomes for men younger than 50 years undergoing radical prostatectomy. Urology 66(1):141–146CrossRefPubMed Twiss C, Slova D, Lepor H (2005) Outcomes for men younger than 50 years undergoing radical prostatectomy. Urology 66(1):141–146CrossRefPubMed
24.
25.
Zurück zum Zitat Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P (2014) Active surveillance for clinically localized prostate cancer–a systematic review. J Surg Oncol 109(8):830–835. doi:10.1002/jso.23584 CrossRefPubMed Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P (2014) Active surveillance for clinically localized prostate cancer–a systematic review. J Surg Oncol 109(8):830–835. doi:10.​1002/​jso.​23584 CrossRefPubMed
26.
Zurück zum Zitat Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI (2011) A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol 59(1):88–95. doi:10.1016/j.eururo.2010.10.003 CrossRefPubMed Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI (2011) A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol 59(1):88–95. doi:10.​1016/​j.​eururo.​2010.​10.​003 CrossRefPubMed
28.
Zurück zum Zitat Noone AM, Schussler N, Negoita S, Adamo M, Cronin K, Cyr J, Gress D, Grove C, Kosary C, Liu B, Sun L, Ward K, Penberthy L (2015) Availability of TNM staging data elements in the medical record and training needs assessment: results from the 2014 SEER training needs assessment for TNM study. J Regist Manag. 42(2):40–47 Noone AM, Schussler N, Negoita S, Adamo M, Cronin K, Cyr J, Gress D, Grove C, Kosary C, Liu B, Sun L, Ward K, Penberthy L (2015) Availability of TNM staging data elements in the medical record and training needs assessment: results from the 2014 SEER training needs assessment for TNM study. J Regist Manag. 42(2):40–47
Metadaten
Titel
Prostate cancer in men aged less than 50 years at diagnosis
verfasst von
N. J. Kinnear
G. Kichenadasse
S. Plagakis
M. E. O’Callaghan
T. Kopsaftis
S. Walsh
D. Foreman
Publikationsdatum
12.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 11/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1824-4

Weitere Artikel der Ausgabe 11/2016

World Journal of Urology 11/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.